“We’re obviously disappointed that it is taking a little longer to get back into the market,” Caruso said on a conference call with stock market analysts. He said company surveys showed the brands were still trusted by consumers. “That gives us great confidence that the significant legacy that has been built over the years still remains with consumers and they will accept the products once we get them back on the shelves in a continuous way.”
The Fort Washington plant ceased production in April 2010. McNeil plants in Lancaster and Puerto Rico are operating, but under greater government scrutiny as part of a court-ordered consent decree that followed negotiations with the U.S. Food and Drug Administration. Consumers complained that products had a musty smell and they found tiny metal particles in some liquids. The company later attributed the musty smell to chemicals used to treat wooden pallets. McNeil has shifted production to other plants, but well-known products are frequently missing from area store shelves.
In the legal arena, J&J, which had $16.1 billion in revenues for the latest quarter, was penalized $1.2 billion last week by an Arkansas judge after a jury found the company illegally marketed the antipsychotic drug Risperdal through that state’s Medicaid program. That was the third loss in state cases. The U.S. attorney in Boston asked a judge to compel incoming CEO Alex Gorsky to give a deposition in a federal case because Gorsky was in charge of Janssen Pharmaceuticals, the subsidiary that sold Risperdal.
J&J spokesman Louise Mehrotra said Tuesday that the company was seeking a new trial in Arkansas and, if denied, it would appeal last week’s decision. She was not asked by analysts about Gorsky and she did not comment on that matter.
Meanwhile, Caruso said the company has satisfied regulators in Japan, China, and Canada regarding its proposed $21.3 billion acquisition of medical device maker Synthes Inc., which has its U.S. headquarters in West Chester, but was awaiting antitrust approval from the European Commission and the U.S. Federal Trade Commission. J&J hopes that selling the trauma products from its current device division, DePuy, to Biomet will be enough.
“We believe this divestiture will satisfy all regulatory concerns,” Caruso said.
An FTC spokesman declined comment.
Contact David Sell at 215-854-4506, email@example.com or Twitter @PhillyPharma. Read his PhillyPharma blog on philly.com.